NR1I2 and congenital rubella syndrome: Pharmaco-immunomodulatory agents, including tocilizumab that targets at IL-6 of CRS and glucocorticoids (dexamethasone, methylprednisolone, and hydrocortisone), and ritonavir affected PXR regulation.